While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Transparency is the order of the day as Médecins Sans Frontières calls for more disclosure on vaccine deals signed by Sanofi/GSK and other companies. 

NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.